Deals In Depth: February 2013
Biogen paid over $3 billion to buy out Elan’s share of Tysabri. Mylan and Cardinal Health made two billion-dollar-plus acquisitions. FOPOs represented over 50% of the $827 million in biopharma financing. The $322 million in device fundraising was dominated by late-stage venture rounds.